Bladder Cancer

FDA prioritizes review of enfortumab vedotin and pembrolizumab for muscle-invasive bladder cancer, showing promising results in reducing recurrence and mortality.

New trial results reveal that combining pembrolizumab and enfortumab vedotin significantly enhances survival rates in muscle-invasive bladder cancer patients.

Atezolizumab significantly enhances survival in ctDNA-positive muscle-invasive bladder cancer patients, addressing critical treatment gaps post-surgery.

Atezolizumab significantly enhances disease-free and overall survival in ctDNA-positive muscle-invasive bladder cancer patients, reshaping treatment strategies.

Disitamab vedotin plus toripalimab significantly enhances survival rates in HER2-expressing advanced urothelial carcinoma, outperforming standard chemotherapy.

New findings reveal that perioperative enfortumab vedotin and pembrolizumab significantly enhance survival rates in muscle-invasive bladder cancer patients.

New findings reveal that adding durvalumab to chemotherapy enhances survival in muscle-invasive bladder cancer without harming quality of life.

Durvalumab enhances disease-free survival in high-risk non-muscle invasive bladder cancer when combined with BCG therapy, according to recent trial results.

New research suggests using mpMRI for bladder cancer staging improves survival rates, potentially changing standard diagnostic practices.

Atezolizumab shows no significant benefit over BCG alone in treating high-risk non-muscle invasive bladder cancer, according to the ALBAN trial results.

Petros Grivas, MD, PhD, discusses the overall survival and quality-of-life findings from the JAVELIN Bladder 100 trial of avelumab as maintenance therapy for advanced bladder cancer.

Vote on the latest breakthroughs in renal and bladder cancer at ESMO 2025, featuring pivotal late-breaking abstracts.

Explore the latest advancements in muscle-invasive bladder cancer treatment, including immunotherapy and novel therapies enhancing patient outcomes.

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive bladder cancer patients ineligible for cisplatin.

During a live event, Matthew Galsky, MD, discussed adjuvant and neoadjuvant treatment approaches for muscle-invasive bladder cancer.

The ANZUP 1301 trial showed that BCG and mitomycin showed similar DFS to BCG alone in NMIBC, but with 40% fewer BCG doses and similar safety.

A phase 1b trial plans to evaluate AKY-1189 for the treatment of Nectin-4–expressing tumors.

Lisa Herms, PhD, discussed findings from a retrospective analysis from the US community oncology setting on biomarker testing for bladder cancer.

The FDA ODAC decided that the overall benefit-risk of the investigational therapy UGN-102 is not favorable in patients with recurrent low-grade, intermediate-risk NMIBC.

Colin P.N. Dinney, MD, PhD, discussed updated analyses of the BOND-003 and CORE-001 trials in bladder cancer.

Disitamab vedotin plus toripalimab showed significant survival benefits vs chemo in first-line HER2+ advanced urothelial carcinoma, with a manageable safety profile.

Durvalumab plus full BCG significantly improved disease-free survival in high-risk early bladder cancer vs BCG alone in the POTOMAC trial.

Bladder cancer patients undergoing radical cystectomy after pelvic radiotherapy showed increased risks of rectal injury, readmission, sepsis, and surgical-site infections compared with primary surgery.

A phase 3 trial showed neoadjuvant mitomycin C before TURBT in NMIBC patients was safe. While 12-month recurrence-free survival was similar to standard care, an 18-month trend suggested a possible delayed benefit.